- **Scinai Immunotherapeutics Ltd.** entered into a Standby Equity Purchase Agreement with **YA II PN, LTD.** on **September 10, 2025**, granting the company the right, but not the obligation, to sell up to **$15 million** of its American Depositary Shares (ADSs) over a **36-month** period.  **[1611747_0001213900-25-086668_ea025695401ex99-1_scinai.htm:0]** **[1611747_0001213900-25-086668_ea0256954-6k_scinai.htm:1]** 
- The purchase price for the ADSs will be **97%** of the lowest of the three daily Volume Weighted Average Prices (VWAPs) during a three-consecutive trading day period, with the company able to specify a minimum acceptable price per ADS.  **[1611747_0001213900-25-086668_ea0256954-6k_scinai.htm:1]** **[1611747_0001213900-25-086668_ea025695401ex99-1_scinai.htm:5]** 
- A commitment fee of **$108,000** is payable to the investor, with **50%** paid by the issuance of **35,461 ADSs** and the remaining **50%** in cash.  **[1611747_0001213900-25-086668_ea0256954-6k_scinai.htm:1]** 
- The investor's beneficial ownership is limited to **9.99%** of the company's then-outstanding voting power or number of Ordinary Shares.  **[1611747_0001213900-25-086668_ea0256954-6k_scinai.htm:1]** **[1611747_0001213900-25-086668_ea025695401ex99-1_scinai.htm:4]** 
- This new agreement will automatically terminate a prior Standby Equity Purchase Agreement dated **March 3, 2025**, between the Company and Yorkville, upon the effectiveness of a new registration statement.  **[1611747_0001213900-25-086668_ea0256954-6k_scinai.htm:1]** **[1611747_0001213900-25-086668_ea025695401ex99-1_scinai.htm:33]**

Scinai Immunotherapeutics Enters $15 Million Equity Purchase Agreement

- Scinai Immunotherapeutics Ltd. reported **revenues of $773 thousand** for the six months ended June 30, 2025, a significant increase from **$284 thousand** in the same period of 2024, reflecting continued growth in its CDMO business.  **[1611747_0001213900-25-083373_ea025545201ex99-1_scinai.htm:0]** 
- The company's net loss for the six months ended June 30, 2025, was **$4,134 thousand**, a decrease from **$4,481 thousand** in the prior year, primarily due to higher revenues and lower R&D expenses.  **[1611747_0001213900-25-083373_ea025545201ex99-1_scinai.htm:0]** 
- Research and development expenses for the six months ended June 30, 2025, amounted to **$1,237 thousand**, down from **$2,788 thousand** for the same period in 2024.  **[1611747_0001213900-25-083373_ea025545201ex99-1_scinai.htm:0]** 
- As of June 30, 2025, cash and cash equivalents totaled **$989 thousand**. Subsequently, in July and August 2025, the company raised an additional **$4.2 million** through its Standby Equity Purchase Agreement.  **[1611747_0001213900-25-083373_ea025545201ex99-1_scinai.htm:0]** 
- Scinai is advancing its anti-IL-17 NanoAb program and plans to apply for up to **€15 million** in grant financing under the EU STEP program, with a decision expected in Q1 2026.  **[1611747_0001213900-25-083373_ea025545201ex99-1_scinai.htm:0]**

Scinai Immunotherapeutics (SCNI)